Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02417961 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
- 20
- Study locations
NCT02417961 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 162 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT02417961, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess functionality, performance, and reliability of an accessorized pre-filled syringe (APFS) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab administration in asthma patients with severe asthma.
Conditions Studied
Interventions
- BIOLOGICAL Benralizumab
Study Locations (20)
Florida
- Research Site - Celebration
- Research Site - Ocala
- Research Site - Orlando
- Research Site - Winter Park
Ontario
- Research Site - Ajax
- Research Site - Burlington
- Research Site - Mississauga
- Research Site - Toronto
California
- Research Site - Fountain Valley
- Research Site - Walnut Creek
Quebec
- Research Site - Montreal
- Research Site - Pointe-Claire
Georgia
- Research Site - Albany
Minnesota
- Research Site - Minneapolis
Missouri
- Research Site - St Louis
Nebraska
- Research Site - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2016-03-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02417961
The ClinicalTrials.gov registry entry for NCT02417961 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (90% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Benralizumab is the first listed.
NCT02417961 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT02417961 about?
NCT02417961 is a clinical study titled "Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home". The purpose of the study is to assess functionality, performance, and reliability of an accessorized pre-filled syringe (APFS) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver, and to confirm the safety and clinical benefit of benralizumab...
What is the current status of trial NCT02417961?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2015-04-27. Estimated completion is 2016-03-14.
What conditions does trial NCT02417961 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02417961?
The interventions under investigation include: Benralizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02417961?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02417961 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.